JP2014525939A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014525939A5 JP2014525939A5 JP2014527142A JP2014527142A JP2014525939A5 JP 2014525939 A5 JP2014525939 A5 JP 2014525939A5 JP 2014527142 A JP2014527142 A JP 2014527142A JP 2014527142 A JP2014527142 A JP 2014527142A JP 2014525939 A5 JP2014525939 A5 JP 2014525939A5
- Authority
- JP
- Japan
- Prior art keywords
- ifnλ1
- complex
- pharmaceutical composition
- peg
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 102100020990 Interferon lambda-1 Human genes 0.000 claims 6
- 101710099623 Interferon lambda-1 Proteins 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 230000002035 prolonged effect Effects 0.000 claims 4
- 229960000329 ribavirin Drugs 0.000 claims 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 4
- 230000009385 viral infection Effects 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- -1 4-nitrophenoxycarbonyl Chemical group 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 claims 2
- 229950006081 taribavirin Drugs 0.000 claims 2
- 230000003442 weekly effect Effects 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 238000009739 binding Methods 0.000 claims 1
- 230000009702 cancer cell proliferation Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| VN201102222 | 2011-08-25 | ||
| VNVN1-2011-02222 | 2011-08-25 | ||
| PCT/US2012/027317 WO2013028233A1 (en) | 2011-08-25 | 2012-03-01 | Peg-interferon lambda 1 conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014525939A JP2014525939A (ja) | 2014-10-02 |
| JP2014525939A5 true JP2014525939A5 (enrdf_load_stackoverflow) | 2015-04-09 |
Family
ID=47746747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014527142A Withdrawn JP2014525939A (ja) | 2011-08-25 | 2012-03-01 | ペグインターフェロンλ１複合体 |
Country Status (9)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3416675T3 (pl) * | 2016-02-19 | 2021-10-11 | Eiger Biopharmaceuticals, Inc. | Leczenie zakażenia wirusem zapalenia wątroby typu delta za pomocą interferonu lambda |
| ES3015227T3 (en) | 2017-03-16 | 2025-04-30 | Evangelos Andreakos | Use of lambda interferons in the treatment of an obesity-related disorder, atherosclerosis or a coagulation disorder |
| RU2678332C1 (ru) * | 2017-09-08 | 2019-01-28 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") | Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения |
| CN112245570A (zh) | 2019-07-22 | 2021-01-22 | 厦门特宝生物工程股份有限公司 | 一种基于干扰素的疾病治疗方法 |
| KR20230157947A (ko) | 2021-01-21 | 2023-11-17 | 샤먼 아모이탑 바이오테크 컴퍼니 리미티드 | 암 재발 방지를 위한 방법 및 약제학적 조합 |
| KR20230157313A (ko) | 2021-01-21 | 2023-11-16 | 샤먼 아모이탑 바이오테크 컴퍼니 리미티드 | 인터페론-기반 암 치료 방법 및 약제학적 조합 |
| WO2024121424A1 (en) | 2022-12-09 | 2024-06-13 | Daniel Zagury | Composite aids vaccine generating anti-hiv specific neutralizing antibodies and/or anti-hiv cytotoxic t cells |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| CN1176137C (zh) * | 2002-01-15 | 2004-11-17 | 泛亚生物技术有限公司 | 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用 |
| CN1927388B (zh) * | 2004-09-10 | 2011-02-02 | 北京金迪克生物技术研究所 | 含有人干扰素的药物组合物 |
| WO2006133089A2 (en) * | 2005-06-03 | 2006-12-14 | Ambrx, Inc. | Improved human interferon molecules and their uses |
| DK1931704T3 (da) * | 2005-10-04 | 2011-03-14 | Zymogenetics L L C | Frembringelse og rensning af IL-29 |
| CN101002942B (zh) * | 2007-01-08 | 2010-07-21 | 湖南大学 | 一种peg化脂质体纳米颗粒 |
| EP2296691A1 (en) * | 2008-06-05 | 2011-03-23 | ZymoGenetics, L.L.C. | Use of pegylated type iii interferons for the treatment of hepatitis c |
-
2012
- 2012-03-01 AU AU2012299423A patent/AU2012299423A1/en not_active Abandoned
- 2012-03-01 RU RU2014111179/10A patent/RU2014111179A/ru not_active Application Discontinuation
- 2012-03-01 JP JP2014527142A patent/JP2014525939A/ja not_active Withdrawn
- 2012-03-01 CA CA2846092A patent/CA2846092A1/en not_active Abandoned
- 2012-03-01 CN CN2012800033678A patent/CN103228792A/zh active Pending
- 2012-03-01 BR BR112014004302A patent/BR112014004302A2/pt not_active IP Right Cessation
- 2012-03-01 WO PCT/US2012/027317 patent/WO2013028233A1/en unknown
- 2012-03-01 EP EP12825651.8A patent/EP2748328A4/en not_active Withdrawn
-
2014
- 2014-02-14 ZA ZA2014/01159A patent/ZA201401159B/en unknown